)
Edge6 Feb 2026
SharkNinja: Viral by Design
How SharkNinja built a repeatable growth engine, turning overlooked appliance categories into global brands through consumer insight and iteration.
Foghorn Therapeutics
Foghorn Therapeutics (FHTX) investor relations material
Foghorn Therapeutics Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary11 Feb, 2026
Scientific rationale and target selection
Chromatin regulatory system and BAF complex mutations are implicated in over 50% of cancers, making them high-value but historically challenging targets due to loss-of-function alterations and similarity to healthy cell machinery.
Advances in understanding have revealed these complexes are central to disease, not just cellular maintenance, opening new therapeutic opportunities.
Selective targeting is difficult, but the breadth of application and limited competition make these targets attractive.
Pipeline overview and development strategy
Lead program SMARCA2, in partnership with Eli Lilly, targets cancers with SMARCA4 loss, especially non-small cell lung cancer, using a synthetic lethal approach.
Additional wholly owned programs focus on CBP (ER-positive breast cancer), EP300 (hematological malignancies), and ARID1B, all pursued via targeted protein degradation.
Selectivity is achieved by comparing chemical matter against full protein complexes, enabling identification of allosteric binders for SMARCA2.
Clinical progress and market opportunity
SMARCA2 phase I trial began dosing in October 2024, with global sites open and prioritization of non-small cell lung cancer patients with SMARCA4 loss.
Approximately 15,000 US patients annually could benefit, with global potential much higher.
Dose escalation is ongoing, with backfilling in relevant cohorts; decision on dose expansion expected around mid-year.
Monotherapy efficacy is a key goal before moving to combinations, with plans for combination cohorts (e.g., with pembrolizumab) in expansion phase.
SMARCA2: What clinical activity is needed?
CBP/EP300: How does selectivity improve profile?
Beyond synthetic lethal: What new opportunities?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Foghorn Therapeutics earnings date
Q4 20256 Mar, 2026
Foghorn Therapeutics
Next Foghorn Therapeutics earnings date
Q4 20256 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company specializing in the discovery and development of novel therapies targeting the chromatin regulatory system, which plays a critical role in gene expression and cellular identity. The company leverages its proprietary Gene Traffic Control platform to gain an integrated understanding of how chromatin regulation affects disease, enabling it to identify and develop potential drug candidates. Foghorn's research focuses on treating genetically determined dependencies in various cancers, including hematologic malignancies and solid tumors. The company has collaborations with major pharmaceutical firms to further its therapeutic pipeline. Foghorn Therapeutics is headquartered in Cambridge, Massachusetts, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage